St. Jude Care & Treatment

Menu

Close

Recruiting

NPPRALL: Blood Tests for Childhood Leukemia

About this study

Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Most children with ALL are cured. But doctors need better ways to see how well treatment is working. Some patients may do well with less treatment. Others may need more treatment to keep the cancer from coming back.

NPPRALL is studying a new blood test. The test looks for tiny pieces of cancer DNA in the blood. These pieces are called cell-free DNA (cfDNA). The study also looks at how the immune system changes during treatment. The immune system helps the body fight disease, including cancer.

Patients with ALL, lymphoblastic lymphoma, or mixed phenotype acute leukemia may join this study if they are already taking part in the INITIALL clinical trial. This is not a treatment study. Patients will continue to receive their regular cancer treatment.

Patients will give blood samples at different times during their treatment. Samples will be collected during routine blood draws so extra needle sticks are not needed. Researchers will also collect information about the patient's cancer, treatment, and how well the treatment is working.

Researchers hope these blood tests will make it easier to see how patients respond to treatment. They also want to learn how the immune system changes during therapy. The goal is to learn if these blood tests can help doctors know which patients are responding well to treatment and which patients may need more tests or follow-up care.

Eligibility overview

  • Ages 1–18 years 
  • Acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia
  • Enrolled in the INITIALL study

Request a referral

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

NPPRALL: New Peripheral Predictors of Response for Acute Lymphoblastic Leukemia

Study goal:

To study cell-free DNA and immune markers in acute lymphoblastic leukemia to improve treatment-response monitoring.

Diagnosis:

Acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia

Age:

1–18 years old

Clinical trial categories:

Lymphoma Childhood Cancer Acute Lymphoblastic Leukemia (ALL) Leukemia

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more